As the title implies, this final rule clarifies and amends the discount safe harbor at 42 C.F.R. § 1001.925(h) under the federal Anti-kickback statute (AKS) such that rebates paid from drug manufacturers to Medicare Part D prescription drug plan sponsors or their pharmacy benefit managers (PBMs) are not protected from liability under the discount safe harbor. The rule also adds a new safe harbor for point-of-sale reductions in price that are passed on directly to a buyer (a defined term under the rule) and an additional safe harbor for “legitimate” service fees paid to PBMs by drug manufacturers.
OIG Finalizes Rebate Rules: Removal of Safe Harbor Protections for Rebates and Creation of New Safe Harbors for Other Discounts and Service Fees
More Issues
Wade’s Health Law Highlights for November 17, 2026
OIG approved a drug manufacturer’s plan to pay for autoantibody testing that helps determine whether its drug for a rare lung disease may be…
Wade’s Health Law Highlights for November 10, 2026
Texas secured a $45 million settlement with Gilead Sciences over manufacturer patient support programs it treated as illegal inducements under state law. The Texas…
Wade’s Health Law Highlights for November 3, 2026
HHS will not take enforcement action against 503A compounding pharmacies that make six peptides FDA removed from the compounding bulks list in 2023. The…
